The PSG is the largest non-profit clinical trial site network in North America conducting PD research. It is composed of over 155 sites with more than 375 credentialed investigators. It was formed in 1986, prompted by the recognition that clinical research in Parkinson disease (PD) required the participation of large numbers of research patients under the cooperative care of skilled and experienced research physicians, coordinators and allied professionals.
Since 1986, PSG has carried out cooperative therapeutic research beginning with the NIH-sponsored DATATOP (Deprenyl and Tocopherol Antioxidative Therapy of Parkinsonism) clinical trial. To date, the PSG has carried out more than 35 multi-center trials examining the symptomatic and neuroprotective effects of experimental interventions in Parkinson disease.
The PSG was officially designated a 501c3 non-profit organization in August of 2016. We have successfully partnered with numerous pharmaceutical companies and the National Institute of Health (NIH) in bringing new drugs for Parkinson disease to the market including pramipexole, entacapone, rotigotine and rasagiline.